<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03716102</url>
  </required_header>
  <id_info>
    <org_study_id>IP-18-001</org_study_id>
    <nct_id>NCT03716102</nct_id>
  </id_info>
  <brief_title>OPTIMIZE Sirolimus-Eluting Coronary Stent Systems Pharmacokinetics (PK) Study</brief_title>
  <official_title>OPTIMIZE Sirolimus-Eluting Coronary Stent Systems Pharmacokinetics (PK) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Svelte Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Svelte Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetic parameters of sirolimus release from the Svelte DES.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open, non-randomized, study involving two (2) centers in the United
      States. A minimum of twelve (12) and a maximum of fifteen (15) subjects will be consented,
      treated and have blood samples drawn to evaluate the pharmacokinetic parameters of sirolimus
      release from the Svelte DES.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 21, 2018</start_date>
  <completion_date type="Anticipated">July 15, 2021</completion_date>
  <primary_completion_date type="Actual">June 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed blood concentration (Cmax)</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum blood concentration (tmax)</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the blood concentration versus time curve: time zero to the final quantifiable concentration) (AUC 0-t)</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the blood concentration versus time curve: time zero to the extrapolated infinite time (AUC 0-∞)</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal phase half-life (t1/2)</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total blood clearance (CL/F)</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vd/F)</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>6 months, 12 months, 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Svelte DES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stent: A mounted Cobalt Chromium (Co-Cr) alloy based stent Polymer coating: Polyesteramide (PEA) Sirolimus drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PCI with implantation with DES</intervention_name>
    <description>PCI with implantation with DES</description>
    <arm_group_label>Svelte DES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is an eligible candidate for PCI

          -  Subject has symptomatic coronary artery disease with objective evidence of ischemia or
             silent ischemia

          -  Subject is an acceptable candidate for CABG

          -  Subject has ≤ 3 de novo target lesions in ≤ 2 native coronary artery vessels, with ≤ 2
             lesions in a single vessel, each meeting the angiographic criteria and none of the
             exclusion criteria

          -  Target lesion(s) must be located in a native coronary artery with RVD ≥ 2.25mm and ≤
             4.00mm

        Exclusion Criteria:

          -  Subject has cardiogenic shock, hemodynamic instability requiring inotropic or
             mechanical circulatory support, intractable ventricular arrhythmia, or ongoing
             intractable angina

          -  Subject's target lesion(s) is located in the left main coronary artery

          -  Subject's target lesion(s) is located within 3mm of the origin of the LAD or LCX
             coronary artery

          -  Subject's target lesion(s) is located within a SVG or an arterial graft

          -  Subject's target lesion(s) will be accessed via SVG or arterial graft
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Donohoe, MD</last_name>
    <role>Study Director</role>
    <affiliation>Svelte Medical Systems</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Hospital d.b.a McLaren Northern Michigan</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

